Trial Profile
Safety and Tolerability Study of Combination Nivolumab and Cabiralizumab as Neoadjuvant and Adjuvant Therapy for Resectable Biliary Tract Cancer
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 14 Apr 2020
Price :
$35
*
At a glance
- Drugs Cabiralizumab (Primary) ; Nivolumab (Primary)
- Indications Biliary cancer
- Focus Adverse reactions
- 09 Apr 2020 Status changed from recruiting to withdrawn prior to enrolment.
- 07 Aug 2019 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 Jun 2019 to 1 Sep 2019.
- 05 Jul 2019 Status changed from not yet recruiting to recruiting.